Dyne Therapeutics Upgraded at Oppenheimer Following Positive Read-Through from Avidity Biosciences Trial Data

Oppenheimer has upgraded Dyne Therapeutics (DYN) based on positive read-through from data that Avidity Biosciences (RNA) is set to release this year from a late-stage trial for one of its lead candidates. The upgrade is due to the potential implications of Avidity's results for Dyne's own pipeline, specifically its focus on RNA-targeting therapeutics.